The Animal Models for Protecting Ischemic Myocardium Study was undertaken for the purpose of developing reproducible animal models that could be used to assess interventions designed to limit infarct size. This paper describes the results obtained in an unconscious dog model and in a conscious dog model, developed in three participating laboratories. The unconscious dog model, involving reperfusion after 3 hours of ischemia in open-chest dogs, was intended to determine whether therapy followed by early reperfusion would limit infarct size more than reperfusion alone. The conscious dog model used chronically instrumented dogs and permanent coronary occlusion to better mimic myocardial infarction in man. In both models, the proximal circumflex artery was occluded, and the primary experimental endpoint was infarct size, as measured by histological techniques 3 days after the initial occlusion. Infarct size was analyzed in relation to baseline variables including the anatomic area at risk, collateral blood flow to the subepicardial zone of ischemia and hemodynamic determinants of myocardial metabolic demand. Most of the variation in infarct size in control dogs could be related to variation in the area at risk, collateral blood flow, and rate pressure product. Using multivariate analysis and groups of 15 dogs, an intervention that limited infarct size by 10-13% of the area at risk would have been detected 50% of the time. Larger treatment effects would be detected more readily, and smaller effects often would be missed, unless group sizes were larger. Two drugs, verapamil and ibuprofen, were evaluated in both models, with experimental group sizes averaging 13 and 20 dogs, in the unconscious and conscious models, respectively. Three of 15 verapamil-treated dogs in the unconscious model study had much smaller infarcts than expected from baseline parameters. With these exceptions, neither drug limited infarct size in either model. (Circ Res 56: 651-665, 1985) WITH most potential therapies to protect ischemic myocardium, some studies have shown dramatically positive results, whereas others have shown no benefit. To achieve a better understanding of the major factors that determine infarct size and to develop two, well-characterized, standardized canine models of myocardial infarction, collaborative studies were • The AMPIM (Animal Models January 24-25, 1978, which concluded that, while many promising animal models existed for studying protection of ischemic myocardium, more standardization of these models was required to improve comparability of results betiveen different laboratories. The NHLBI undertaken in three independent laboratories, as a part of the NHLBI-sponsored Animal Models for Protecting Ischemic Myocardium (AMPIM) program.* The unconscious model studied at Duke (DU) was designed to determine whether therapy can reduce the amount of cell death developing in the recommended that three different coronary-occluded preparations be studied: (1) the rat, for relatively inexpensive and rapid screening of potentially useful treatments; (2) the anesthetized dog, for verification of effectiveness in a more physiological situation; and (3) the conscious dog, for testing the most promising agents under the most physiological conditions. Studies reported here were on anesthetized dogs (Duke Medical Center: Reimer et al.) and on conscious dogs (Duke Medical Center: Cobb et al; and The Johns Hopkins University: Becker et al).
open-chest dog heart as a consequence of 3 hours of ischemia. This model was viewed as intermediate, to screen for therapeutic effects. The conscious model studied at the Durham Veterans Administration Medical Center (DVA) and at The Johns Hopkins University (JH) was designed to test the effect of therapy following permanent occlusion. The conscious model was believed to simulate better the state of patients with acute myocardial infarction. To evaluate the precision and reproducibility of these experimental models, two agents, verapamil and ibuprofen, as well as a placebo control, were tested.
Methods

Animal Selection and Exclusion Criteria
Adult mongrel dogs of either sex, weighing 10-25 kg, were used. No beagles or pregnant animals were included. No dogs were accepted into the study with a hematocrit <35, clinically evident infection, or circulating heart worm filariae. Obese dogs also were avoided, and the thickness of subcutaneous fat was measured during thoracotomy. Dogs that were entered and that later were found to have heart worms were excluded from analysis. Data were collected, to the extent possible, on all dogs that died before termination of the study. However, infarct size was measured only in dogs that survived until sacrifice; dogs that died prematurely have been excluded.
Preparation for Study
Unconscious Model
Dogs were fasted overnight prior to study. They were anesthetized with 30-40 mg/kg of iv sodium pentobarbital, and additional doses were given as needed throughout the experiment. The dogs were intubated and ventilated at 200 ml/kg per min of room air. Aseptic surgical technique was used, and 1,000,000 units of penicillin were given im as a prophylaxis against infection. Catheters were placed in the femoral vein and artery. The arterial catheter was connected to a Statham model P23ID transducer to monitor blood pressure. Arterial blood gases were checked, and the ventilation rate and/or oxygen flow rate were adjusted to achieve physiological blood gas values (Po 2 : 100-140 mm Hg, Pco 2 : 32-40 mm Hg, and pH 7.37-7.47) before thoracotomy. A 6 to 8-cm thoracotomy then was performed in the 4th intercostal space and the heart was suspended in a temporary pericardial cradle. The proximal circumflex artery was isolated 1.5-2.0 cm from the origin and was encircled with a 00. silk suture so that the artery could be occluded with an atraumatic clamp. Two catheters were placed into the left atrium via the left atrial appendage to monitor pressure and inject microspheres. Fluid loss was replaced with saline at a continuous infusion rate of 2.5 ml/kg per hr.
Conscious Model
Dogs were anesthetized with thiamylal sodium (30-40 mg/kg, iv) and underwent left thoracotomy through the 4th intercostal space. Heparin-filled polyvinyl chloride catheters were positioned in the aortic root, the left atrium via the left atrial appendage, and a systemic vein. A mechanical adjustable snare type occluder was placed around the proximal left circumflex coronary artery above or below the first marginal branch, so that temporary occlusion resulted in cyanosis of at least 75% of the inferior Circulation Research/Vol. 56, No. 5, May 1985 wall. The catheters and snare were either exteriorized (JH) or positioned in a subcutaneous pocket at the back of the neck (DVA). Penicillin, 1,000,000 units, and streptomycin, 1.0 g, were given im for the first 4 postoperative days, and for at least 7 days were allowed for recovery from surgery. Dogs were fasted overnight prior to study, which was carried out in a noise-free, dimly lit room with the animal either lying on a padded table (DVA) or standing supported in a sling (JH). After exteriorization and/or flushing of the catheters, 30-40 minutes were allowed for the animals to adjust to the laboratory conditions. Morphine sulfate, 0.25 mg/kg, im, was given 30 minutes before occlusion, and an additional 0.25 mg/kg, iv, was given 20 minutes later. No additional analgesics were used.
In both models, heart rate and aortic and left atrial pressures were monitored continuously. A test dose of 0.6-1.0 ml of 0.05% Tween-80 was injected into the left atrial catheter to minimize subsequent hemodynamic reactions to microsphere injections containing Tween-80. No antiarrhythmic drugs were used in either the conscious or unconscious model. Dogs that developed ventricular fibrillation were excluded from analysis.
Coronary Occlusion
Unconscious Model
Coronary occlusion was performed suddenly, with an atraumatic Schwartz vascular clamp. The occlusion was maintained for 3 hours, and then was removed in one stage. The presence of reperfusion was confirmed by the appearance of an epicardial blush. The thoracotomy was closed in layers, and air was evacuated from the chest.
Conscious Model
Permanent coronary occlusion was produced by a sudden one-stage tightening of the snare occluder.
Randomization of Treatment Groups
In both models, dogs were randomized (Peto et al., 1976) into three treatment groups: verapamil, ibuprofen, or control (ibuprofen vehicle). Randomization was done 5 minutes after coronary occlusion by drawing a drug identification code number from a sealed envelope supplied by NIH. Drug infusion was begun 15 minutes after coronary occlusion. Because verapamil has hypotensive effects, the identity of vials containing this drug was not hidden. However, investigators were blinded with respect to ibuprofen vs. vehicle controls.
Drug Regimens
Verapamil was diluted from ampules containing 2.5 mg of drug/ml and was administered at an initial rate of 0.03 mg/kg per min for 5 minutes and then at 0.01 mg/kg per min for the 3 hours of occlusion in the unconscious model, and for 6 hours in the conscious model. The infusion rate was slowed by 20% if diastolic blood pressure decreased by more than 20 mm Hg below pretreatment values, or to less than 70 mm Hg, or if heart rate increased by more than 20 beats/min. Ibuprofen or placebo was diluted from refrigerated ampules containing 50 mg of blinded drug/ml and was administered at an initial rate of 2.5 mg/kg per min for 5 minutes and then at 6.25 mg/kg per hour for the duration of coronary occlusion in the unconscious model, and for 24 hours in the conscious model. In the latter situation, a self-contained back pack with a Cormed battery powered infusion purnp was used.
Measurements Recorded in Vivo
Hemodynamic measurements, including heart rate, systolic and diastolic blood pressure, mean left atrial pressure, and mean arterial pressure, were taken 5 minutes before occlusion and 10, 25,105, and 180 minutes after occlusion. Measurements were repeated at 6 hours in the conscious model. Arterial blood gases were measured 10 minutes before and 10 minutes after occlusion in both models.
Measurements of Regional Myocardial Blood Flow
Myocardial blood flow was measured with microspheres (9 ± 1 M m) labeled with 46 Sc, 85 Sr, 95 Nb, or 141 Ce (Rivas et al., 1976; Jugdutt et al., 1979a; Reimer and Jennings, 1979a) . Measurements were made 5 minutes before and 10 and 105 minutes after occlusion in both models, and at 6 hours after occlusion in the conscious model. Microspheres were obtained from stock solutions containing 10% dextran and 0.01-0.02% Tween-80. These solutions were agitated in an ultrasonic bath for 15 minutes and mixed on a Vortex agitator prior to injection. We determined flow, in each instance, by injecting approximately 2-3,000,000 microspheres into the left atrium over a 15-second period, followed by a 10-ml saline flush. A reference arterial blood flow sample was collected with a constant withdrawal pump beginning 5 seconds before sphere injection and continuing for 1.5 to 2.5 minutes, at a rate of 5-15 ml/min.
Postmortem Analyses
In both models, the experiment was terminated at 72 hours after reanesthesia and administration of 5000 units of iv heparin.
Myocardium at Risk
Unconscious Model. Myocardium at risk was assessed by postmortem dye injection of occluded and unoccluded coronary beds (Reimer and Jennings, 1979a) . Catheters were placed in the unoccluded left main coronary artery and the proximal left circumflex artery. Both vessels were perfused simultaneously for approximately 3 minutes at identical pressures of 120-140 mm Hg at 37°C. The perfusion fluid was sodium phosphate buffer (8.8 X 10~2 mol dibasic and 0.18 X 10~2 mol monobasic sodium phosphate/liter, pH 8.25-8.6) plus 6% dextran (82,000 mol. wt., Sigma), to which either 1.0% triphenyltetrazolium chloride (TTC) (for perfusion of the previously occluded vascular bed) or 0.05% monastral blue dye (for perfusion of the remainder of the left ventricle) was added. The heart was then fixed by immersion in a large volume of phosphate-buffered formalin. The left ventricle was sectioned into eight transverse slices. The slices were weighed, and the apical surfaces photographed. The previously occluded vascular bed (area at risk) was identified and traced from enlarged projections of the photographic slide of each ventricular slice. The area at risk was measured by "cut-and-weigh" techniques using copies of these tracings as previously described (Reimer and Jennings, 1979a) .
Conscious Model. The myocardium at risk was assessed by postmortem injection of the proximal left circumflex artery and the nonoccluded left main artery with barium sulfate suspended in gelatin, perfused at pressures of 120-140 mm Hg (Jugdutt et al., 1979a) . The hearts were fixed in 10% formalin solution for 2-4 days. After x-rays had been taken, the heart was sectioned in eight transverse rings, and each was radiographed. The region supplied by the occluded vessel (risk region), was identified by x-rays of the whole left ventricle and rings, and marked on tracings of each ring. Occluded bed mass was determined by direct excision and weighing (DVA), or by planimetry of tracings of the four rings (JH).
Histological Analysis
The method of sampling for histological and blood flow analysis is shown in Figure 1 . The basal half of the four composite slices, plus the apical half of the apical slice were used for histological analysis. Sections were stained with hematoxylin and eosin (and at DU with Heidenhain's variant of Mallory's connective tissue stain). Infarct size was determined for each slice and for the heart as a whole using cut-and-weigh techniques with copies of enlarged photographs or traced projections of these histological sections.
Regional Blood Flow
Flow measurements were made using the apical half of each of the top three composite slices (Fig. 1 ). The slices were divided into the following zones for regional myocardial blood flow analysis: (1) nonischemic zone, (2) central ischemic zone (central 50% of the vascular bed at risk), (3) septal border zone (septal 25% of the vascular bed at risk), and (4) lateral border zone (lateral 25% of vascular bed at risk). However, in the present paper, only the collateral flow of the central ischemic zone is reported and analyzed. Data from septal and lateral samples have been excluded to avoid misinterpretation of measurements from samples which may have contained nonischemic as well as ischemic myocardium. These regions were further subdivided into subendocardial, mid-myocardial, and subepicardial thirds. Regional myocardial blood flow was calculated by the formula,
Qm = Qr x Cm Cr
where Qm = myocardial blood flow (ml/min); Qr = reference blood flow (ml/min); Cm = counts/min in myocardial sample; Cr = counts/min in reference sample. The myocardial blood flow was expressed relative to the tissue sample weight (ml/min per g). Corrections were made for true and/or apparent microsphere loss (Reimer and Jennings, 1979b; Capurro et al., 1979; Jugdutt et al., 1979b; Murdock and Cobb, 1980) . True and/or apparent microsphere loss was calculated by the following equation:
where MBF PO = preocclusion blood flow in individual samples of the region subjected to ischemia, MBF N , = mean flow in nonischemic samples from the same layer. Ischemic blood flow measurements were then corrected for each sample using the following equation:
MBF C = MBF U X 100 100 -% apparent microsphere loss'
where MBF C = corrected blood flow values, MBF U = unconnected blood flow values, and % apparent microsphere loss = the percent loss from preceding equation.
Data Analysis
The postmortem sampling procedures and quantitative analysis were done by individuals who did not know the treatment of any given dog. Data forms were submitted 
The area of infarction in this plane was considered to be representative of the full thickness of each slice, for conversion of infarct surface area to infarct weight. Blood flow was measured in the nonischemic region, central ischemic zone (central 50% of the infarct), and septa! and lateral border zones. Each of these regions was further subdivided into inner, middle, and outer thirds. The individual flow data illustrated in this paper is the arithmetic mean of blood flow measured in the three slices. Because of probable contamination of some septa! and lateral border samples with nonischemic myocardium, data from these samples has not been included in this paper.
to NIH, where all data were computerized for subsquent analysis. At the end of the study, the drug identification code was broken and data from all three laboratories were compared.
Comparisons of histological, hemodynamic, and flow measurements were made among treatments, between conscious model sites, and between models, using simple two-sample f-tests. When differences between pre-and post-treatment values were studied, these differences were computed for each animal and then compared by twosample /-tests, as desired, among groups. Paired f-tests were used to determine whether any pre-post treatment differences existed.
Because of the major importance of area at risk, collateral flow, and cardiac metabolic demand in determining infarct size, these parameters were incorporated into the statistical analysis of infarct size, using rate pressure product as an index of metabolic demand.
Two methods were used to control for area at risk and collateral flow. The first was to relate infarct size to area at risk by expressing infarct size as a percent of area at risk. Infarct size (as % of area at risk) then was compared among treatments in an analysis of covariance using collateral blood flow as the covariate. This method has the advantage of simplicity and ease of interpretation, since the relationship can be displayed graphically using observed data. On the other hand, it makes an assumption that the relationship of infarct size to area at risk goes through the origin (i.e., that infarct size will be proportional to area at risk). The method also assumes that treatment effect will be proportional to area at risk. Moreover, this method permits incorporation of only one variable in addition to area at risk.
The second method used to control for baseline variables was to fit a multiple linear regression model with baseline variables as independent variables, and infarct size as the dependent variable. This method does not depend on the above-mentioned assumptions and permits simultaneous analysis of several independent variables. Treatment effects were entered into this multiple regression model as treatment-specific intercepts and coefficients for the independent variables. By estimating models both with and without treatment specific coefficients, it was possible to assess whether the regression equations were different for different treatment groups. Two multiple linear regression models were considered, an additive and a multiplicative model. In the additive model it was assumed that infarct size could be predicted by a linear combination of the three variables, area at risk, subepicardial collateral blood, and rate pressure product (RPP). In the multiplicative model, the three independent variables were area at risk, and the products of area at risk X subepicardial collateral and area at risk X RPP. Both models were estimated; the results were very similar. We present only the multiplicative analysis herein, based on the rationale that differences in collateral flow or RPP may have more of an effect on infarct size when area at risk is large than when it is small. (At the extreme, if area at risk is zero, flow differences should have virtually no effect on infarct size.)
Results
Animal Selection and Mortality (Table 1)
Unconscious Model
Fifty-one dogs were entered into the study and all were randomized. One dog was pregnant at the time of study and was excluded. In addition, two dogs had minimal reductions of coronary blood flow following occlusions, probably due to failure of the (81) 6(60) 10 (91) 8 (67) 24 (73) 14 (100) 11 (100) 13 (87) 38 (95) 20 (83) Schwartz clamp, and have been excluded. Nine dogs (19%) died prior to sacrifice. Of these, five developed ventricular fibrillation during the first hour of coronary occlusion (two during the first 15 minutes); one died 55 minutes after reperfusion, and the other three died of unknown cause (presumably ventricular fibrillation) during the 3 days between acute study and sacrifice. Thus, infarct size was analyzed in 39 of the dogs randomized. Of the dogs included in the final analysis, 38% were male, mean weight was 14 kg ± 2.5, and hematocrit was 40 ± 3.2%. There were no significant differences among treatment groups in these parameters.
Conscious Model
Ninety-one dogs were entered into the study, of which 84 were randomized. Seven dogs were excluded prior to randomization because of technical difficulties arising from the prior instrumentation. Eleven randomized dogs also were excluded for several reasons: four at DVA and two at JH for heart worms, two for occlusion failure at JH, one at each center for receiving incomplete therapy, and one at DVA because of failure to obtain histology. Nine of 33 (27%) of the remaining dogs studied at JH and two of 40 (5%) dogs at DVA died before sacrifice and have been excluded. All 11 deaths occurred 12 hours or more after occlusion. In the combined conscious study, infarct size was analyzed in 62 of the 84 randomized dogs. Of these dogs, 56% were male, mean weight was 20 ± 2.3 kg, and hematocrit was 42 ± 4.2%. Most of the dogs at DVA were male, and most at JH were female.
Comparison of Baseline Parameters by Model and Site (Tables 2-6)
Hemodynamic parameters measured 10 minutes after coronary occlusion and before treatment (baseline measurements) are listed in Tables 2 and 3 . Comparison of the results from each study site showed some consistent hemodynamic differences between the unconscious and conscious models and between the JH and DVA conscious study sites. Mean heart rate was higher in the unconscious dogs (158 vs. 121 beats/min) and resulted in a higher rate-pressure product. Systolic and diastolic arterial pressures and left atrial pressures were similar in the two models. However, the mean systolic blood pressure and left atrial pressure were higher at JH compared to DVA. Within each study site, however, no significant hemodynamic differences between control and treatment groups were detected.
Despite the higher rate-pressure product, coronary blood flow to nonischemic myocardium was lower in the unconscious than conscious dogs (Tables 4 and 5). The reason for this paradox is unknown. A possible cause is reduced contractility in the unconscious model; however, indices of myocardial contractility were not measured. In addition, baseline central ischemic collateral blood flow was Results are expressed as mean ± SD. Heart rate is in beats/min, and all pressures are in mm Hg. Significant changes between the 10and 105-minute measurements within a group, by paired (-analysis, are indicated by * P <0.05; \ P <0.01. Significant differences between control and treated groups are indicated as + P <0.05, §P <0.01. Significant differences between the unconscious and conscious models are indicated by || P <0.05, 11 P < 0.01. Hemodynamic parameters for all groups 5 minutes before coronary occlusion were: heart rate 156±27; systolic blood pressure 154±19; diastolic blood pressure 107±13; mean left atrial pressure 4.3±1.8; rate pressure product (x 10~2) 241±53. Coronary occlusions had a significant effect on all of these parameters except heart rate. lower in the unconscious dogs. The reason for this difference in collateral blood flow also is unknown. The sampling protocol was designed to prevent admixture of nonischemic and ischemic tissue, but we cannot be certain that the higher collateral flows in the conscious dogs was not due, in part, to such admixture. Another more likely reason for higher collateral flow in the conscious dogs is that snare placement around the circumflex artery induced collateral growth in some dogs. Finally, the smaller areas at risk at JH also may have contributed to the higher collateral flows. Baseline nonischemic and collateral coronary blood flow did not differ significantly between the JH and DVA groups. Within each study site, measurements of collateral coronary flow following randomization and treatment also did not differ between control and treatment groups.
The anatomic area at risk averaged 41% of the left ventricle in both unconscious and conscious models (Tables 6 and 7) . However, the mean area at risk was smaller at JH (35%) than at DVA (45%), apparently due to use of a somewhat more distal occlusion site at JH. Again, within each study site, the area at risk was comparable in treatment groups.
Treatment Effects on Hemodynamic Parameters and Coronary Blood Flow
Unconscious Model
In the unconscious model, coronary occlusion caused a reduction in blood pressure but no change in heart rate (see footnote to Table 2 ). In the control group, the major hemodynamic change between 10 and 105 minutes after occlusion was an increase Units are as defined for Table 2 . Statistical significance for various comparisons also is indicated-as defined for Table 2-except that || P <0.05 and 1 P <0.01 refers to comparison of JH vs. DVA results. Hemodynamic parameters for all groups 5 minutes prior to coronary occlusion were: heart rate 91±19; systolic blood pressure 136±22; diastolic blood pressure 85±16; mean left atrial pressure 4.1±3.2; rate pressure product (x 10~2) 125±38. Coronary occlusion had a significant effect on all of these parameters except systolic blood pressure. outer (subepicardial) thirds of the myocardium. Statistical significance for various (partial recovery) in systolic and diastolic blood pressure (Table 2) . Nonischemic and central ischemic collateral blood flow were unchanged between 10 and 105 minutes of coronary occlusion (Table 4 ). In the ibuprofen group, blood pressure also increased between 10 and 105 minutes ( Table 2) . Mean heart rate was moderately lower and left atrial pressure moderately higher in both control and treated groups at 105 vs. 10 minutes, but the changes were significant only in the ibuprofen group. Neither nonischemic nor central ischemic collateral flow was affected by ibuprofen (Table 4 ). In contrast, verapamil decreased heart rate and blood pressure and increased left atrial pressure ( Table 2 ). The effects of verapamil on nonischemic and central ischemic collateral coronary blood flow were minor.
Conscious Model
In the conscious model, coronary occlusion caused increases in both heart rate and diastolic blood pressure (see footnote to Table 3) , and arterial and left atrial pressure decreased between 10 and 105 minutes after occlusion. These effects were directionally opposite to those observed in the unconscious model. Between 10 and 105 minutes, nonischemic and central ischemic collateral blood flow did not change in the combined group (Table 5) , but nonischemic flow decreased in the DVA group. Ibuprofen reduced heart rate in the conscious model, as it did in the unconscious model. Nonischemic coronary blood flow decreased between 10 and 105 minutes in the ibuprofen group at the DVA but not at JH, paralleling the observations in the control groups at the same sites. Ibuprofen did not significantly alter central ischemic collateral blood flow (10 vs. 105 min) at either conscious study site, but subepicardial collateral flow was higher prior to treatment in the ibuprofen group vs. controls studied at DVA. In the combined conscious verapamil groups, the only significant hemodynamic effects were slight reductions in diastolic arterial and left atrial pressures. However, the hemodynamic effects of verapamil differed between JH and DVA, the major effect at JH being an increased heart rate without a decrease in blood pressure, and the major effect at DVA was a decrease in pressure without change in heart rate. Nonischemic coronary blood flow was modestly increased after verapamil therapy, but central ischemic collateral blood flow was unchanged. Comparison of the overall response to verapamil in conscious vs. unconscious dogs indicated that the cardiodepressant effects of the drug were more pronounced in the unconscious model.
Analysis of Infarct Size Variability among Control Dogs
Unconscious Model
Infarct size (Table 6 ) in control dogs averaged 26% of the left ventricle, with a sizeable standard deviation (±14% of the LV). Much of this variation in infarct size could be related to variation in the anatomic area at risk (r 2 = 0.77) ( Fig. 2A) . When infarct size was normalized to the area at risk, infarct size averaged 60% ± 27% (SD) of the area at risk in the control group.
Central ischemic collateral flow varied considerably among dogs and this variation was greatest in the subepicardial region (0.20 ± 0.15 ml/min per g). In the unconscious control dogs, the relationship between infarct size (as a percent of the area at risk) and central ischemic subepicardial flow measured 10 minutes after coronary occlusion is shown in Figure 3A . About 50% of the variation in infarct size, normalized to area at risk, was explained by the variation in subepicardial collateral flow (r 2 = 0.53). The rate-pressure product, an index of myocardial metabolic demand, did not contribute significantly to variation in infarct size in a univariate analysis (the correlation coefficient for infarct size/ area at risk vs. the rate-pressure product was only 0.26). Based on the relationship illustrated in Figure  3A , and assuming group sizes of 15 dogs, a 13% (of area at risk) limitation of infarct size would be detected at a significance level of P < 0.05 about 50% of the time. Larger treatment effects would be where IS = infarct size, AAR = area at risk, CBF = subepicardial collateral blood flow, and RPP = ratepressure product. The numbers in parentheses are standard errors of the coefficients. The r 2 value was 0.90, and the residual standard deviation was 0.052 or 5.2% of the left ventricle. This model accounted for 90% of the variation in infarct size observed in the study; 77% of the variation was attributable to area at risk alone. Based on this multiple regression model, and assuming group sizes of 15 dogs per group, a 10% (of area at risk) limitation of infarct size would be detected at a significance level of P < 0.05 about 50% of the time. 
Conscious Model
Infarct size (Table 7) among control dogs (6 from JH and 13 from DVA) had about the same degree of variability observed in the unconscious model, averaging 22% ± 14% of the LV and 49% ± 23% of the area at risk. The relation between infarct size (as % of LV) and area at risk in the conscious study is illustrated in Figure 2B . As with the unconscious model, based on r 2 = 0.66, most (66%) of the variation in infarct size was related to the size of the area at risk. Infarct size (as % of LV) was slightly smaller at JH (18%) compared with DVA (22%), a difference which was clearly related to smaller areas at risk in the dogs studied at JH. Infarct size, normalized as % of area at risk, was similar at the two conscious dog study sites (48 and 49%, respectively).
As was observed with the unconscious model, conscious dogs showed a transmural gradient in central ischemic collateral blood flow, with considerable variation among dogs in the amount of collateral flow to the subepicardial region (0.40 ± 0.21 ml/min per g). As in the unconscious model, part of the variation in infarct size (normalized to area at risk) was accounted for by variation in central ischemic collateral blood flow r 2 = 0.40 and 0.18 at DVA and JH, respectively) ( Fig. 3B) . Based on the relationship in Figure 3B and assuming group sizes of 15 dogs, a 13% (of area at risk) limitation of infarct size would be detectable at a significance level of P < 0.05 about 50% of the time.
In contrast to the unconscious model, the ratepressure product was significantly related to infarct size/area at risk in the conscious model (r 2 = 0.23). When the multiple regression model was fit to conscious control dogs, the resulting equation (« = 20) was: is = 0.04 + AAR X [0.50 -(0.59 X CBF) + (1.82 X RPP/10 5 )] (0.10) (0.23) (0.32) (0.64)
The regression had an t 2 = 0.80 with a residual standard deviation of 0.067 or 6.7% of LV. The model thus accounted for 80% of the variability in infarct size; 66% of the variability was accounted for by risk region alone. Based on the multiple regression relationship, and assuming group sizes of 15 dogs, a 13% (of area at risk) limitation of infarct size would be detected at a significance level of P < 0.05 about 50% of the time.
Effects of Verapamil or Ibuprofen on Infarct Size and Ancillary Variables
Unconscious Model
The relationship between infarct size (as a percent of area at risk) and central ischemic subepicardial collateral blood flow is illustrated in Figure 4A . There was a trend toward protection with verapamil, in that at least three individual points were conspicuously below the relationship observed in control animals. However, by this method, comparison of regression lines of control animals vs. verapamil-or ibuprofen-treated dogs failed to show that either drug significantly limited infarct size.
The multiple regression equations for the ibuprofen-and verapamil-treated dogs were: is = 0.13 + AAR X [0.188 -(1.14 X CBF) +(1.49 X RPP/10 5 )] (0.11) (0.31) (0.17) (0.52)
Verapamil IS = 0.04 + AAR X [0.041 -(0.60 X CBF) + (1.48 X RPP/10')] (0.10) (0.25) (0.33) (0.53)
The r 2 values for these equations were 0.88 and 0.49, respectively, and the residual standard deviations were 3.6 and 7.0, respectively. The equation for verapamil dogs was significantly different from that for control dogs, based either on an F-test comparing all four coefficients between treatments, or on a Ntest comparing only the coefficients for area at risk. In the first case, the comparison of all four coefficients yielded F(4,18) = 3.09, P = 0.042. Figure 5A is a plot of actual infarct size vs. infarct size predicted by the multiple regression model. A protective treatment effect in individual dogs is suggested by points falling below the line of identity. At least three verapamil dogs had infarct sizes markedly below the line of identity. The significant difference between control and verapamil-treated groups, using the above multiple regression analysis, clearly was due primarily to these three dogs. No clear effect of therapy occurred in most (12 of 15) of the dogs treated with this drug.
Conscious Model
The relationship between infarct size as a percent of area at risk and central ischemic subepicardial collateral blood flow is illustrated in Figure 4B . As in the unconscious model, comparison of regression lines of control dogs vs. verapamil-or ibuprofentreated dogs by this method failed to show significant limitation of infarct size by either drug. It is of Figure 3 is illustrated for control, but also for verapamil-treated, and ibuprofen-treated infarcts from the unconscious (panel A) and conscious (panel B) studies. Each point represents an individual dog. Open circles represent control dogs, triangles are verapamil-treated dogs, and solid points are ibuprofen-treated dogs. In panel A, the linear correlation coefficient for verapamil treated infarcts is r = -0.38 and for ibuprofen-treated infarcts is r = -0.84. The low r value for the verapamil group is due to three infarcts which were smaller than expected on the basis of baseline collateral flow. However, with these possible exceptions, neither verapamil nor ibuprofen altered the relationship between infarct size and subepicardial collateral flow. In panel B, data from JH and VA has been combined. For verapamil, r = -0.67 (jH r = -0.79 and DVA r = -0.43) and for ibuprofen, r = -0.70 (]H r = -0.51 and DVA r = -0.81). Neither therapy altered the relationship between infarct size and collateral blood flow. However, several ibuprofen-treated dogs at DVA (arrows) had relatively high baseline collateral blood flow and correspondingly small infarcts. Thus, an apparent protective effect with ibuprofen suggested in Table 7 clearly was due to random selection bias. Without the analysis of infarct size in relation to baseline collateral blood flow, an erroneous conclusion, that ibuprofen limited infarct size in the DVA study, could have been drawn. particular interest to note that when infarct size is considered without regard to collateral flow (Table  5) , the difference between control and treated groups at DVA (infarct size/area at risk = 49% vs. 34%) approached significance (P < 0.1). This tendency toward infarct limitation in the treated group was entirely explained by the chance selection of several dogs with unusually high baseline central ischemic collateral flows (measured prior to treatment) into this treatment group (Fig. 4B) . The multiple regression equations for ibuprofen and verapamil dogs were: The r 2 values were 0.71 and 0.62, and the residual standard deviations were 0.071 and 0.075, respectively, for ibuprofen and verapamil. There were no statistically significant differences among the three equations, based either on tests comparing all four regression coefficients or on Mests comparing only the coefficient for area at risk. Figure 5B displays actual infarct sizes plotted against the expected infarct size based on the multiple regression model. In this analysis, there were no treated animals which had infarct sizes markedly below the line of identity.
Discussion
Rationale of Models
Choice of Animal Species and Duration of Coronary Occlusion
Dogs were selected for study, in part, because of the past experience of the investigators involved, but also because canine myocardial infarcts resemble human infarcts in several respects. Most occur in the presence of some residual coronary perfusion via subepicardial collateral anastomoses (Becker et al., 1973; Wusten et al., 1974; Rivas et al., 1976; Williams et al., 1976; Reimer and Jennings, 1979a; Kuo et al., 1982) , the location is related to the vascular distribution of the occluded artery(ies) (Reimer and Jennings, 1979a; Lee et al., 1981; Factor et al., 1981 Factor et al., , 1982 Murdock et al., 1983) , and the subendocardial zone is more susceptible than the subepicardial zone to infarction (Rivas et al., 1976; Reimer and Jennings, 1979a; Lee et al., 1981) .
In the unconscious model, infarction was induced by a temporary (3-hour) occlusion of the proximal left circumflex artery, followed by reperfusion. In this model, some subepicardial myocardium is still viable at 3 hours, even without pharmacological therapy (Reimer and Jennings, 1979a ) and a 10% limitation of infarct size can be achieved by reperfusion. Thus, an intervention that could at least delay cell death could increase the amount of myocardium that could be salvaged by reperfusion Jennings, 1979a, 1984) . The occlusion was permanent in the awake models to produce a more Circulation Research/Vol. 56, No. 5, May 1985 prolonged period of ischemia and a more rigorous test of therapeutic efficacy.
Dose, Time of Initiation, Duration of Therapy
The initial loading dose and rate of verapamil infusion were selected to be the largest that did not cause marked detrimental hemodynamic changes. The dose of ibuprofen was chosen based on previous studies which had shown limitation of infarct size (Jugdutt et al., 1980) . In both models, drug administration was begun 15 minutes after coronary occlusion to permit baseline measurements of postocclusion hemodynamic parameters and coronary collateral blood flow so that the effect of therapy on these potential determinants of infarct size could be observed.
In the unconscious model, therapy was continued throughout coronary occlusion and for 15-30 minutes after reperfusion. In the conscious model, verapamil and ibuprofen were discontinued after 6 and 24 hours of coronary occlusion, respectively. The decision to discontinue therapy at these times was based on the difficulty of maintaining chronic drug delivery and on previous studies that had shown limitation of infarct size following temporary therapy with ibuprofen (Lefer and Polansky, 1979; Jugdutt et al., 1980; Lefer and Crossley, 1980; Romson et al., 1980) .
Choice of Experimental Endpoints: Methods of Measurement
Since our primary objective was to develop protocols to determine whether therapy can limit infarct size, the primary endpoint was the direct measurement of infarct size. Among published anatomic studies, gross staining techniques using triphenyl tetrazolium chloride (TTC) or nitroblue tetrazolium chloride (Lie et al., 1975; Fallon, 1979 ) have been used more commonly than histological techniques. Gross staining techniques have the advantage of being less time consuming and less expensive. However, we chose histological methods because positive staining of myocardium with TTC may not necessarily be synonymous with myocyte viability, and because resolution of the complex interdigitations between necrotic and viable areas can be done most reliably by histological evaluation. The decision to end the studies at 3 days was based on the progressively easier task of histological infarct sizing with passing time, balanced by the fact that infarct repair results in the gradual replacement of infarct by scar, which may not represent accurately the initial infarct size (Reimer and Jennings, 1979b) .
Because infarct size varies considerably among untreated dogs, additional parameters that may influence infarct size must also be measured. Previous studies have shown that variation in infarct size in dogs is related to variation in (1) the size of the ischemic region (area at risk) (Lowe et al., 1978; Reimer and Jennings, 1979a; Jugdutt et al., 1979a; Schaper, 1979) , (2) collateral blood flow to the ischemic region (Rivas et al., 1976; Reimer and Jennings, 1979a; Jugdutt et al., 1979a; Schaper, 1979; Gottwick et al., 1981) , and (3) myocardial metabolic demand which is determined in part by hemodynamic parameters, including heart rate, wall tension, and myocardial contractility (Schaper et al., 1979) .
In this study, the area at risk of undergoing infarction was defined as the anatomic region supplied by the occluded coronary artery (Reimer and Jennings, 1979a; Jugdutt et al., 1979a; Lee et al., 1981) , as distinguished from a "physiological" risk region (DeBoer et al., 1980) , defined as the area with moderate or severe ischemia, based on the paucity of myocardial staining by dyes injected in vivo. The anatomic definition of area at risk was chosen in this study because (1) it is a baseline constant, determined by coronary anatomy, which cannot be altered by spontaneous or therapeutically induced fluctuation in collateral blood flow during an experiment, and (2) identification of an anatomic vascular region requires the identification of boundaries between two vascular regions but does not require the arbitrary distinction between severely vs. less severely ischemic myocardium based on a graded concentration of injected dyes or particles.
Two methods of identifying the anatomic area at risk were used: In the unconscious reperfusion model, in which collateral growth had not been induced, the area at risk could be identified by the boundary between the two different-colored dyes (Reimer and Jennings, 1979a) . Precise sampling of ischemic and nonischemic areas for blood flow analysis was possible because vascular boundaries are seen directly on the ventricular slices. However, in the setting of permanent (3-day) coronary occlusions, new collaterals develop such that dyes in fluid suspension may readily cross the ischemic/nonischemic interface. Thus, in the conscious model, coronary arteries were injected postmortem with radioopaque material, and vascular bed boundaries were identified on radiographs of serial slices of the ventricle (Jugdutt et al., 1979a (Jugdutt et al., , 1979c (Jugdutt et al., , 1980 Lee et al., 1981; Murdock et al., 1983) . The radiographic technique allows direct anatomic delineation of vascular bed boundaries, which are not influenced by collateral growth. The principle limitations of the radiographic techniques are the overlap of vasculature on two-dimensional representation of three-dimensional myocardial slices, and relative imprecision of using x-rays to guide the sampling of myocardium for blood flow analysis.
Tissue sampling for evaluation of collateral blood flow was designed with two major objectives: (1) to select central ischemic samples that were uncontaminated by nonischemic myocardium interdigitating with infarcted myocardium at the boundaries of the ischemic region, and (2) to measure the transmural distribution of collateral blood flow in the central ischemic zone.
Importance of Baseline Variables to Improve Precision and Prevent Erroneous Conclusions
Although, in a randomized study, baseline variables would tend to be balanced across treatments, it is important to control for them statistically in a "small" study in which 30% of the animals are excluded. Controlling for baseline variables improves precision of estimated effects while giving some protection against bias from imbalances in baseline factors due to treatment-dependent exclusions.
Analysis of the control infarcts at each of the three sites confirmed that the area at risk, collateral blood flow, and rate pressure product each were independent determinants of infarct size. Indeed, variation in the size of the area at risk accounted for over half the variation in infarct size (as % of LV), and when collateral flow and rate pressure product were included in the model, 90% of the variation among unconscious controls, and 80% of the variation among conscious control infarcts could be explained. The crucial importance of incorporating collateral blood flow into the analysis is best illustrated by the DVA results with ibuprofen. If infarct size had been evaluated alone, (e.g., based on Table 7) , without respect to collateral blood flow, it could have been concluded erroneously that ibuprofen limited infarct size in the DVA arm of the study (but not at the other two sites). When collateral flow was taken into account, however (Fig. 4B) , it was readily apparent that the smaller infarcts in the ibuprofen-treated group at DVA were due to the random selection into this group, of several dogs with unusually high native levels of collateral blood flow. Conversely, in the unconscious model, the positive verapamil treatment effect seen in 3 of 15 dogs was undetectable without adjustment for baseline variables. In comparison to area at risk or collateral blood flow, ratepressure product was only a weak predictor of infarct size. However, it is recognized that determinants of myocardial metabolic rate and systolic blood pressure include not only heart rate and systolic blood pressure, but also contractility and cardiac size. Whether a more precise estimate of cardiac MVO 2 would have proven to be a better predictor of infarct size in this study is not known; only 10% of the variation in infarct size remained unaccounted for by the baseline parameters measured in this study.
Effect of Therapy with Verapamil or Ibuprofen on Infarct Size
Verapamil and ibuprofen were selected as the two drugs for study, because these drugs represented two general classes of drugs, with presumably different mechanisms of myocardial protection, which had previously shown considerable promise as possible therapies to limit infarct size.
The hypothesis that calcium antagonists protect ischemic myocardium has been tested in a large number of laboratories, using a variety of experimental models and different endpoints [see Jennings, 1984 and 1985 (in press) , for detailed review]. At least five studies have shown limitation of experimental infarct size with calcium antagonists when measured at times ranging from 6 hours to 2 days after coronary occlusion (Henry et al., 1978; DeBoer et al., 1980; Zamanis et al., 1982; Alps et al., 1983; Yellon et al., 1983; Melin et al., 1984) . In contrast, several studies have failed to show salvage of ischemic myocardium with various calcium antagonists (Karlsberg et al., 1977; Geary et al., 1982; Alps et al., 1983; Reimer and Jennings, 1984) . The reason(s) that calcium antagonists have shown protective effects in some studies but not in others is not known. These differences may have been due to differences among the individual drugs or the dose regimens used, to different responses to therapy among different animal models used, or to failure in many studies, to consider one or more of the important baseline determinants of infarct size.
The nonsteroidal anti-inflammatory agent, Ibuprofen, has been studied much less extensively than verapamil, but was selected because it has produced marked reduction of ischemic injury in cats (Lefer and Polansky, 1979; Lefer and Crossley, 1979) , and because it had limited infarct size by over 50% in a conscious dog model (Jugdutt et al., 1980; Romson et al., 1980) . Subsequent to the initiation of these studies, Romson et al. (1982a Romson et al. ( , 1982b , observed limitations of infarct size in an unconscious dog reperfusion model in which infarction was induced by 60 minutes of circumflex coronary occlusion. Chambers et al. (1983) , concluded that flurbiprofen, a fluorinated derivative of ibuprofen, delayed the evolution of TTC evidence of infarction in unconscious dogs but did not limit ultimate infarct size.
The explanation for the discrepancies between those studies showing limitation vs. no limitation of infarct size with nonsteroidal anti-inflammatory agents is not known. However, none of the studies discussed above have made careful analyses of the relation between infarct size and collateral blood flow in treated and untreated dogs.
Conclusions
The goal of these studies was to establish experimental models which could be used to demonstrate reproducibly whether a particular therapy could limit experimental infarct size. Three major sources of variation in infarct size in either unconscious or conscious dogs have been confirmed; 90% of the variation in infarct size among control dogs was related to variation in anatomic area at risk, collateral blood flow, and the rate-pressure product. Methods for measuring these baseline parameters and for including them in the analysis of treatment effects have been standardized. Although neither verapamil nor ibuprofen were shown to limit infarct size, we estimate that by using groups of 15 dogs, and incorporating baseline predictors into the analysis, as little as 10-13% limitation of infarct size would be detected 50% of the time. Larger treatment effects would be more readily detected.
